Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded ...

Blum Holdings ( ($BLMH) ) has issued an update. On December 18, 2025, Blüm Holdings, Inc. closed the acquisition of all outstanding equity of a ...

Detailed price information for Energy Transfer LP (ET-N) from The Globe and Mail including charting and trades.

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM ...

Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approv ...

Liking, wanting, and craving cannabis come from genetics, stress vulnerability, and the desire to "treat" depression, anxiety ...

Instead, the Nvidia (US:NVDA) chief executive was lavishing praise on Schneider Electric (FR:SU), the €140bn (£123bn) French electricals behemoth, whose partnership with Nvidia he anticipates will ...

Mr. Saquib Malik, Director of Vera Enterprises and Mr. Nadeem Patni, Managing Director, Blum India inaugurate new distributor showroom in Bengaluru, Karnataka Bengaluru (Karnataka) [India], December ...

Bring a bold look to kitchens and bathrooms with this curated selection of tiles, hardware, appliances and furniture.

Getting ready for the longest night of the yearThe first day of winter will be Sunday as the winter solstice begins. On that ...

The US Food and Drug Administration (FDA) has approved Cytokinetics’ Myqorzo (aficamten) for the treatment of adults with ...